Tradestie Institutional Equity Comparison Engine

CAMP vs CBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CBIO Overall Edge

CBIO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crescent Biopharma, Inc. Common Stock (CBIO) driven by superior Momentum & Technical, Options & Structure while CAMP counters with relative strength in Growth & Margin. Fundamentally, CAMP trades at N/M Forward P/E with -991.8% operating margin (+138.9% YoY revenue) versus CBIO at N/M Forward P/E and -1228.4% operating margin (+0.0% YoY). In options structure, CAMP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CAMP N/M vs CBIO N/M Fwd P/E
Growth & Margin Winner CAMP
Op Margin -991.8% vs -1228.4% ยท YoY +138.9% vs +0.0%
Momentum & Technical Winner CBIO
1Y -3.7% vs +2.1% ยท 52W Pos 22% vs 24%
Options & Structure Winner CBIO
UNCLASSIFIED (N/A IV) vs BREAKDOWN (10th %ile IV)
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
1M Return +25.8%
1Y Return -3.66%
Forward P/E N/M
Unified AI Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.30
-1.48% 1D
Market Cap $591.3M
1M Return +7.61%
1Y Return +2.15%
Forward P/E N/M
Unified AI Score
42.4 / 100 HOLD
Tech 36.0 Fund 51.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CAMP -3.66% CBIO +2.15% Spread: +5.81 pp (CBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CAMP Revenue CBIO Revenue CAMP Op. Margin CBIO Op. Margin Margin Edge
FY2015 N/A $20M N/A -63.7% CBIO
FY2016 N/A $0M N/A -172505.3% CBIO
FY2020 N/A $10M N/A -506.8% CBIO
FY2021 N/A $0M N/A -5470.7% CBIO
FY2022 N/A $0M N/A -63204.4% CBIO
FY2023 $0M $0M -14822.6% -392752.9% CAMP
FY2024 $0M N/A -8142.3% N/A CAMP
FY2025 $0M $10M -1502.4% -1407.5% CBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CAMP (4) vs CBIO (3)
Institutional Metric CAMP CBIO Criterion Row Winner
Market Capitalization Scale $238.5M $591.3M Larger Scale CBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +138.9% +0.0% Higher Growth CAMP
Operating Margin (TTM) Profitability -991.8% -1228.4% Higher Margin CAMP
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -146.1% -160.8% Higher ROE CAMP
52-Week Range Position Momentum 22% ($3โ€“$8) 24% ($9โ€“$27) Stronger Trend CBIO
Beta / 30D Volatility Risk Regime 1.34ฮฒ ยท 94% Vol 1.38ฮฒ ยท 58% Vol Lower Realized Risk CBIO
Unified Institutional Score Composite Signal 43.9 / 100 (HOLD) 42.4 / 100 (HOLD) Higher Composite CAMP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CAMP vs CBIO Buy Guide
CAMP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CAMP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
145d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live CBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CAMP nor CBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.